entertainment -WSS

entertainment

author：comprehensive 2025-09-27 23:01:13 - browse：73

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： A new approach to psychiatric drug development

WSS

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

First over

For longer

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Investigation reveals sickle cell patients pressured into sterilizations

Cue Health, Covid

focus

entertainment

leisure time

Cancer drug shortages should be causing more outrage

Harvard's David Sinclair gets blowback over aging

What does generative AI mean for health care? We asked experts

The untold story of TV’s first prescription drug ad

How to save PrEP access — and even expand it

Questions and answers about ramping up H5N1 bird flu vaccine

New air purifier tech could be key to improving indoor air quality

State of the Union pitch: Bigger Medicare drug price negotiations

As demand for Covid shots wanes, Moderna seeks its next success

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

hotspot

For AI in health care standards, federal regulators join with industry group

For AI in health care standards, federal regulators join with industry group

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

H5N1 virus can be tracked in retail milk, scientists say

Addressing health care workers' trauma can help fight burnout

Fentanyl is making it harder to start addiction treatment

focus

leisure time

focus

focus